Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:FBRX NASDAQ:NRIX NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$39.61+2.3%$33.02$22.24▼$46.00$2.30B0.541.04 million shs773,957 shsFBRXForte Biosciences$48.86+8.6%$23.24$9.10▼$50.00$624.72M2.85896,642 shs595,739 shsNRIXNurix Therapeutics$23.12+0.2%$19.09$8.19▼$25.08$2.39B1.81.88 million shs794,887 shsVCELVericel$46.64-2.4%$39.57$28.95▼$48.75$2.44B1.07588,527 shs472,154 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+2.30%-3.93%+19.74%+12.72%-0.95%FBRXForte Biosciences+8.60%+11.25%+177.77%+44.04%+404.75%NRIXNurix Therapeutics+0.22%+0.26%+35.05%+32.04%+86.15%VCELVericel-2.45%-0.77%+19.19%+30.72%+25.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$39.61+2.3%$33.02$22.24▼$46.00$2.30B0.541.04 million shs773,957 shsFBRXForte Biosciences$48.86+8.6%$23.24$9.10▼$50.00$624.72M2.85896,642 shs595,739 shsNRIXNurix Therapeutics$23.12+0.2%$19.09$8.19▼$25.08$2.39B1.81.88 million shs794,887 shsVCELVericel$46.64-2.4%$39.57$28.95▼$48.75$2.44B1.07588,527 shs472,154 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+2.30%-3.93%+19.74%+12.72%-0.95%FBRXForte Biosciences+8.60%+11.25%+177.77%+44.04%+404.75%NRIXNurix Therapeutics+0.22%+0.26%+35.05%+32.04%+86.15%VCELVericel-2.45%-0.77%+19.19%+30.72%+25.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.45Hold$42.567.44% UpsideFBRXForte Biosciences 2.50Moderate Buy$67.0037.13% UpsideNRIXNurix Therapeutics 2.79Moderate Buy$34.0847.39% UpsideVCELVericel 2.43Hold$55.5019.00% UpsideCurrent Analyst Ratings BreakdownLatest FBRX, NRIX, AGIO, and VCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2026VCELVericel Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $54.007/13/2026NRIXNurix Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$30.00 ➝ $34.007/10/2026NRIXNurix Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $34.007/10/2026NRIXNurix Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $34.007/10/2026NRIXNurix Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$34.00 ➝ $40.007/10/2026NRIXNurix Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$30.00 ➝ $33.007/10/2026NRIXNurix Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.007/10/2026NRIXNurix Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.007/8/2026FBRXForte Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/7/2026AGIOAgios Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$28.00 ➝ $32.007/7/2026AGIOAgios Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $41.00(Data available from 7/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$54.03M43.60N/AN/A$20.46 per share1.94FBRXForte BiosciencesN/AN/AN/AN/A$4.71 per shareN/ANRIXNurix Therapeutics$83.98M28.57N/AN/A$3.88 per share5.96VCELVericel$276.26M8.62$0.54 per share86.07$7.01 per share6.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%7/30/2026 (Estimated)FBRXForte Biosciences-$69.38M-$4.64N/AN/AN/AN/A-106.17%-85.50%8/13/2026 (Estimated)NRIXNurix Therapeutics-$264.46M-$3.45N/AN/AN/A-928.44%-76.09%-57.31%N/AVCELVericel$16.52M$0.42111.0555.52N/A7.35%6.41%4.61%7/30/2026 (Estimated)Latest FBRX, NRIX, AGIO, and VCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026FBRXForte Biosciences-$1.03N/AN/AN/AN/AN/A7/30/2026Q2 2026AGIOAgios Pharmaceuticals-$1.6588N/AN/AN/A$26.07 millionN/A7/30/2026Q2 2026VCELVericel-$0.04N/AN/AN/A$72.70 millionN/A7/9/2026Q2 2026NRIXNurix Therapeutics-$0.73-$0.81-$0.08-$0.81$15.29 million$9.04 million5/11/2026Q1 2026FBRXForte Biosciences-$1.16-$1.24-$0.08-$1.24N/AN/A5/7/2026Q1 2026VCELVericel-$0.15-$0.12+$0.03-$0.12$63.68 million$68.43 million4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.1913.59FBRXForte BiosciencesN/A2.752.75NRIXNurix TherapeuticsN/A6.346.34VCELVericelN/A5.184.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AFBRXForte Biosciences77.63%NRIXNurix TherapeuticsN/AVCELVericelN/AInsider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals5.40%FBRXForte Biosciences4.40%NRIXNurix Therapeutics6.70%VCELVericel7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionableFBRXForte Biosciences513.89 million13.28 millionOptionableNRIXNurix Therapeutics300103.78 million96.83 millionOptionableVCELVericel30051.07 million47.19 millionOptionableFBRX, NRIX, AGIO, and VCEL HeadlinesRecent News About These CompaniesVericel (NASDAQ:VCEL) Raised to "Buy" at Wall Street Zen11 minutes ago | americanbankingnews.comVericel (NASDAQ:VCEL) Upgraded by Wall Street Zen to Buy Rating12 minutes ago | marketbeat.comVericel Corporation (NASDAQ:VCEL) Given Consensus Rating of "Hold" by BrokeragesJuly 17 at 4:07 AM | americanbankingnews.comVericel (NASDAQ:VCEL) Sets New 52-Week High - Still a Buy?July 16 at 12:19 PM | marketbeat.comVericel to Report Second Quarter 2026 Financial Results on July 30, 2026July 16 at 8:30 AM | globenewswire.comFifth Third Bancorp Purchases 255,465 Shares of Vericel Corporation $VCELJuly 16 at 3:43 AM | marketbeat.comVericel (NASDAQ:VCEL) Stock Price Down 5.9% - Here's What HappenedJuly 14, 2026 | marketbeat.comVericel Stock Short Interest Report | NASDAQ:VCEL | BenzingaJuly 13, 2026 | benzinga.comVericel Corporation (NASDAQ:VCEL) Receives Average Rating of "Hold" from AnalystsJuly 12, 2026 | marketbeat.comGranite Investment Partners LLC Buys 48,056 Shares of Vericel Corporation $VCELJuly 10, 2026 | marketbeat.comIs Vericel (NASDAQ:VCEL) Emerging As A Small-Cap Healthcare Story?July 9, 2026 | kalkinemedia.comKVericel (NASDAQ:VCEL) Reaches New 1-Year High - Still a Buy?July 9, 2026 | marketbeat.comWhich Is a Better Investment, Syndax Pharmaceuticals, Inc. or Vericel Corporation Stock?July 8, 2026 | aaii.comALouisiana State Employees Retirement System Makes New $721,000 Investment in Vericel Corporation $VCELJuly 7, 2026 | marketbeat.comConestoga Capital Advisors LLC Raises Stock Holdings in Vericel Corporation $VCELJuly 2, 2026 | marketbeat.comVericel (NASDAQ:VCEL) Insider Sells 2,732 Shares of StockJuly 1, 2026 | insidertrades.comVericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really SuggestsJune 27, 2026 | fool.comVericel (NASDAQ:VCEL) Insider Sean Flynn Sells 15,000 Shares of StockJune 23, 2026 | insidertrades.comVericel CorporationJune 9, 2026 | edition.cnn.comVericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026June 9, 2026 | globenewswire.comVericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million MoreMay 30, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFBRX, NRIX, AGIO, and VCEL Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$39.61 +0.89 (+2.30%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$39.60 -0.01 (-0.03%) As of 07/17/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Forte Biosciences NASDAQ:FBRX$48.86 +3.87 (+8.60%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$48.78 -0.08 (-0.16%) As of 07/17/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Nurix Therapeutics NASDAQ:NRIX$23.12 +0.05 (+0.22%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$23.12 +0.00 (+0.02%) As of 07/17/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Vericel NASDAQ:VCEL$46.64 -1.17 (-2.45%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$46.64 -0.01 (-0.01%) As of 07/17/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector GE Aerospace Faces a Prove-It Moment in Q2 Earnings Sandisk: What the Chart Is Trying to Tell Us Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Has Broadcom Become Too Expensive for Its AI Story? 3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
